Novel nano-composite particles for controlled-release drugs via inhalation

用于吸入控释药物的新型纳米复合颗粒

• 批准号: LP160101498
• 负责人: Prof Hak-Kim Chan
• 金额: $ 36.12万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-02 至 2021-06-02
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP160101498
• 关键词: Novel; nano; composite; particles; controlled

This project will explore a novel nano-medicine technology using nanocrystals in liposomes to design new composite particles to enable optimal release of antibiotics delivered by inhalation. Respiratory infection caused by multidrug-resistant bacteria is a major health problem worldwide. Controlled-release products using liposomes simplify dose regimen and enhance bacterial killing. Currently, aerosolised liposomes are limited to liquid forms with limited control over release and stability. The project will provide new technology on manufacturing composite powders of antibiotics that may ultimately lead to the development of effective new treatments against drug-resistant bacteria.

该项目将探索一种新型纳米医学技术，使用脂质体中的纳米晶体来设计新的复合颗粒，以实现通过吸入递送的抗生素的最佳释放。由多重耐药细菌引起的呼吸道感染是世界范围内的主要健康问题。使用脂质体的控释产品简化了剂量方案并增强了细菌杀伤力。目前，雾化脂质体限于液体形式，对释放和稳定性的控制有限。该项目将提供制造抗生素复合粉末的新技术，最终可能导致开发针对耐药细菌的有效新治疗方法。